Specialty pharmaceutical market: Treatment patterns and product performance

IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market. The offering supports clients’ critical commercial applications through comprehensive coverage of the specialty pharmacy provider channel, coupled with IMS’s extensive anonymized patient-centered insights.

“This marks a significant advance for our clients that offer specialty medications, all of whom share a vital interest in a market segment that’s growing at twice the pace of traditional pharmaceutical products,” said Pam Sauerwald, general manager, Specialty Offerings Development, IMS. “As demand for evidence-based information in the specialty sector grows, we’re uniquely positioned to provide a deeper understanding into how these products are used – helping clients to adjust portfolio strategies and improve their commercial effectiveness.”

The IMS offering provides unprecedented insights into channel dynamics, with longitudinal information from the specialty pharmacy provider channel that can be applied in combination with retail and standard mail service channel assessments. This enables clients to identify trends and growth opportunities relating to utilization, product switching, compliance and persistence by channel, product usage by indication, common treatment regimens, and channel-to-channel dynamics.

Today, specialty pharmaceutical products dominate R&D pipelines, with global sales expected to exceed $160 billion by 2013. IMS Specialty Market Dynamics already is being used by several leading pharmaceutical companies that offer treatments in key specialty therapeutic areas, including autoimmune biologics and oral oncology.

IMS Specialty Market Dynamics is the latest addition to IMS Specialty SolutionsTM, the company’s portfolio of next-generation market intelligence products and consulting services focused exclusively on specialty markets. Building on uniform information from more than 25 specialty pharmacy providers, IMS Specialty Solutions empowers clients to make evidence-based, commercial decisions faster and with greater efficiency.

Source IMS Health

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination